WebPHOSLYRA - ® is indicated as an adjunct to reduction in dietary intake of phosphate and dialysis to reduce serum phosphorus in patients with kidney failure on dialysis. 2 DOSAGE … WebPhoslyra Prescribing Information. Waltham, MA. Fresenius Medical Care North America. September 2024. 7. Velphoro Prescribing Information. ... Fresenius Medical Care North America. November 2024. 8. Calcium Acetate Gelcaps Prescribing Information. Waltham, MA: Fresenius Medical Care North America; April 2024. 9. Quarles LD, Berkoben M ...
Texas Prior Authorization Program Clinical Criteria Drug/Drug …
WebApr 21, 2024 · PHOSLYRA is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease. Contraindications Hypercalcemia. Precautions WARNINGS AND PRECAUTIONS Treat mild hypercalcemia by reducing or interrupting PHOSLYRA and Vitamin D. Severe hypercalcemia may require hemodialyis … WebThe Related Drug Information Index provides comprehensive access to all drug information related to a specific drug Types of content include full prescribing information, drug … how many miles is 480 km
FDA Label Search
WebMar 14, 2024 · The most common side effects of Phoslyra include: increased calcium in the blood, nausea, and. diarrhea. Tell the doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Phoslyra. For more information, ask your doctor or pharmacist. WebGeneral information about the safe and effective use of Gabapentin Capsules . Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Gabapentin Capsules for a condition for which it was not prescribed. ... For current full prescribing information, please visit www.acihealthcareusa.com ... WebHIGHLIGHTS OF PRESCRIBING INFORMATION 2 DOSAGE AND ADMINISTRATION These highlights do not include all the information needed to use LAMZEDE ® safely and effectively. See full prescribing information for LAMZEDE. LAMZEDE (velmanase alfa-tycv) for injection, for intravenous use Initial U.S. Approval: 2024 . WARNING: SEVERE … how many miles is 4.9 km